- Home
- FPF vs ARQT Comparison
FPF vs ARQT Comparison
Compare FPF & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPF
- ARQT
- Stock Information
- Founded
- FPF 2013
- ARQT 2016
- Country
- FPF United States
- ARQT United States
- Employees
- FPF N/A
- ARQT N/A
- Industry
- FPF Trusts Except Educational Religious and Charitable
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- FPF Finance
- ARQT Health Care
- Exchange
- FPF Nasdaq
- ARQT Nasdaq
- Market Cap
- FPF 1.1B
- ARQT 1.1B
- IPO Year
- FPF N/A
- ARQT 2020
- Fundamental
- Price
- FPF $18.62
- ARQT $13.08
- Analyst Decision
- FPF
- ARQT Strong Buy
- Analyst Count
- FPF 0
- ARQT 5
- Target Price
- FPF N/A
- ARQT $17.00
- AVG Volume (30 Days)
- FPF 186.7K
- ARQT 1.9M
- Earning Date
- FPF 01-01-0001
- ARQT 02-25-2025
- Dividend Yield
- FPF 8.08%
- ARQT N/A
- EPS Growth
- FPF N/A
- ARQT N/A
- EPS
- FPF N/A
- ARQT N/A
- Revenue
- FPF N/A
- ARQT $138,708,000.00
- Revenue This Year
- FPF N/A
- ARQT $215.24
- Revenue Next Year
- FPF N/A
- ARQT $53.63
- P/E Ratio
- FPF N/A
- ARQT N/A
- Revenue Growth
- FPF N/A
- ARQT 182.84
- 52 Week Low
- FPF $13.91
- ARQT $5.38
- 52 Week High
- FPF $18.09
- ARQT $16.20
- Technical
- Relative Strength Index (RSI)
- FPF 56.95
- ARQT 41.94
- Support Level
- FPF $18.45
- ARQT $13.33
- Resistance Level
- FPF $18.85
- ARQT $15.09
- Average True Range (ATR)
- FPF 0.18
- ARQT 0.86
- MACD
- FPF 0.04
- ARQT -0.16
- Stochastic Oscillator
- FPF 74.03
- ARQT 6.25
About FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.